Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib in stage IIIB or IV NSCLC
NCT01031225Phase 2Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Nov 2009
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganetespib in non-small cell lung cancer (NSCLC), sponsored by Synta Pharmaceuticals Corp. Primary endpoint: Progression Free Survival rate at 16 weeks. Started Nov 2009; status: completed.
02
Drugs
ganetespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01031225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031225.